Physician profile
Syed J Umer
NPI 1790741676
$4,670.80
in general payments reported to CMS, 2019-2025
21 companies · $587 in 2025
The $587 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $315 · 2020: $577 · 2021: $363 · 2022: $2,257 · 2023: $225 · 2024: $347 · 2025: $587.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,139 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,138.94 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ge Healthcare | $2,257.01 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $624.96 | 2019-2025 | Lifevest |
| Pfizer INC. | $359.84 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $309.94 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $256.25 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $136.91 | 2024 | Camzyos, Eliquis |
| Abbott Laboratories | $117.34 | 2019-2021 | |
| Amgen INC. | $79.41 | 2020-2025 | Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.96 | 2023-2025 | Jardiance |
| Tactile Systems Technology INC | $71.88 | 2020-2025 | Nimbl, Flexitouch Plus |
| Bayer Healthcare Pharmaceuticals INC. | $63.74 | 2025 | |
| Glaxosmithkline, LLC. | $53.71 | 2020-2025 | Shingrix, Arexvy |
| Novo Nordisk INC | $42.96 | 2025 | Wegovy |
| Scpharmaceuticals INC. | $41.43 | 2025 | |
| Lilly USA, LLC | $38.20 | 2024-2025 | Zepbound, Mounjaro |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $34.78 | 2020 | |
| Sanofi-Aventis U.S. LLC | $31.21 | 2020-2023 | |
| Astellas Pharma US INC | $22.29 | 2019 | |
| Merck Sharp & Dohme LLC | $21.38 | 2021 | |
| Angiodynamics, INC. | $15.96 | 2021 | |
| Biocompatibles, INC. | $15.64 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Syed Umer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.